在患有遗传性血管的患者中,实践结果规定了lanadelumab与其他预防措施的对比
John Anderson1, Daniel Soteres2, Raffi Tachdjian3
1From the Clinical Research, AllerVie Health, Birmingham, Alabama.
Allergy and asthma proceedings
|September 18, 2024
概括
与其他长期预防 (LTP) 患者相比,接受兰阿德鲁马布治疗的遗传性血管炎 (HAE) 患者的发作较少,生活质量更好. 现实世界的数据证实了lanadelumabb的存在.
科学领域:
- 免疫学 免疫学 免疫学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性血管 (HAE) 是一种罕见的遗传性疾病,导致严重的发作.
- 长期预防 (LTP) 对于管理HAE至关重要.
- 现实世界关于LTP有效性的数据有限,包括lanadelumab.
研究的目的:
- 为了比较临床特征,发作频率和生活质量 (QoL) 的HAE患者在兰德鲁马布治疗与其他LTPs.
- 评估接受不同预防治疗的HAE I/II型患者的现实结果.
主要方法:
- 美国医生的横截面调查 (阿德尔菲HAE疾病特定计划,2021年7月至11月).
- 医生报告的数据为144名HAE患者接受兰阿德鲁马布或其他LTP治疗超过12个月.
- 在治疗组之间比较疾病活性,发作史和QoL.
主要成果:
- 拉纳德鲁马布组的攻击频率在数值上较低 (2.3对3.4次攻击/年).
- 接受兰阿德鲁马布治疗的患者报告了显著更高的QOL (72.4%vs36.5%好/非常好).
- 较高比例的lanadelumab患者在诊断时具有高疾病活性和严重疾病.
结论:
- 在现实环境中,lanadelumab治疗与降低HAE攻击频率有关.
- 与其他LTPs患者相比,接受lanadelumab的患者报告了改善的QoL.
- 拉纳德鲁马布在HAE管理方面表现出有利的结果.
相关概念视频
01:19Antiasthma Drugs: Leukotriene Modifiers
252
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
252
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
396
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
396
01:25Antihypertensive Drugs: Direct Renin Inhibitors
508
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
462
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
462
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
139
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
139
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
245
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
245